"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03631420","Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants",,"Active, not recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells","The incidence and frequency of adverse events related to administration of UMC119-01.|The percentage of subjects who died from any cause during the study.|Changes of the oxygen saturation.|Changes of chest x-ray findings in participants before and after administration.|Changes of inflammatory markers (pg/ml) before and after administration.|Comparison of the incidence and severity of preterm children's complications in participants before and after administration.|The number of days of intubation, or where ventilator or oxygen therapy.|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).","Meridigen Biotech Co., Ltd.","All","3 Days to 51 Days Â  (Child)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UMC119-01-001","October 26, 2018","December 31, 2022","July 31, 2025","August 15, 2018",,"April 26, 2021","National Chen-Kung University Hospital, Tainan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03631420"
